354 related articles for article (PubMed ID: 19937650)
1. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
3. Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers.
Yang M; Lei M; Huo S
Protein Sci; 2003 Jun; 12(6):1222-31. PubMed ID: 12761393
[TBL] [Abstract][Full Text] [Related]
4. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into a zinc-dependent pathway leading to Leu55Pro transthyretin amyloid fibrils.
Castro-Rodrigues AF; Gales L; Saraiva MJ; Damas AM
Acta Crystallogr D Biol Crystallogr; 2011 Dec; 67(Pt 12):1035-44. PubMed ID: 22120741
[TBL] [Abstract][Full Text] [Related]
6. Initial conformational changes of human transthyretin under partially denaturing conditions.
Yang M; Lei M; Bruschweiler R; Huo S
Biophys J; 2005 Jul; 89(1):433-43. PubMed ID: 15821170
[TBL] [Abstract][Full Text] [Related]
7. A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation.
Jesus CS; Almeida ZL; Vaz DC; Faria TQ; Brito RM
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589730
[TBL] [Abstract][Full Text] [Related]
8. Hydrogen bonds connecting the N-terminal region and the DE loop stabilize the monomeric structure of transthyretin.
Inada Y; Ono Y; Okazaki K; Yamashita T; Kawaguchi T; Kawano S; Kobashigawa Y; Shinya S; Kojima C; Shuto T; Kai H; Morioka H; Sato T
J Biochem; 2023 Sep; 174(4):355-370. PubMed ID: 37400978
[TBL] [Abstract][Full Text] [Related]
9. The sequence-dependent unfolding pathway plays a critical role in the amyloidogenicity of transthyretin.
Yang M; Yordanov B; Levy Y; Brüschweiler R; Huo S
Biochemistry; 2006 Oct; 45(39):11992-2002. PubMed ID: 17002298
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
Hurshman Babbes AR; Powers ET; Kelly JW
Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
[TBL] [Abstract][Full Text] [Related]
11. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.
Quintas A; Saraiva MJ; Brito RM
FEBS Lett; 1997 Dec; 418(3):297-300. PubMed ID: 9428731
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic Mutations Induce Partial Structural Changes in the Native β-Sheet Structure of Transthyretin and Accelerate Aggregation.
Lim KH; Dasari AKR; Ma R; Hung I; Gan Z; Kelly JW; Fitzgerald MC
Biochemistry; 2017 Sep; 56(36):4808-4818. PubMed ID: 28820582
[TBL] [Abstract][Full Text] [Related]
13. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
Ferrão-Gonzales AD; Palmieri L; Valory M; Silva JL; Lashuel H; Kelly JW; Foguel D
J Mol Biol; 2003 May; 328(4):963-74. PubMed ID: 12729768
[TBL] [Abstract][Full Text] [Related]
14. FRET studies of various conformational states adopted by transthyretin.
Ghadami SA; Bemporad F; Sala BM; Tiana G; Ricagno S; Chiti F
Cell Mol Life Sci; 2017 Oct; 74(19):3577-3598. PubMed ID: 28478513
[TBL] [Abstract][Full Text] [Related]
15. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
16. Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.
Shnyrov VL; Villar E; Zhadan GG; Sanchez-Ruiz JM; Quintas A; Saraiva MJ; Brito RM
Biophys Chem; 2000 Dec; 88(1-3):61-7. PubMed ID: 11152276
[TBL] [Abstract][Full Text] [Related]
17. S-Homocysteinylation effects on transthyretin: worsening of cardiomyopathy onset.
Leri M; Rebuzzini P; Caselli A; Luti S; Natalello A; Giorgetti S; Marchese L; Garagna S; Stefani M; Paoli P; Bucciantini M
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129453. PubMed ID: 31676294
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic versus mutation dependent instability/flexibility: a comparative analysis of the structure and dynamics of wild-type transthyretin and its pathogenic variants.
Lei M; Yang M; Huo S
J Struct Biol; 2004 Nov; 148(2):153-68. PubMed ID: 15477096
[TBL] [Abstract][Full Text] [Related]
19. Localized structural fluctuations promote amyloidogenic conformations in transthyretin.
Lim KH; Dyson HJ; Kelly JW; Wright PE
J Mol Biol; 2013 Mar; 425(6):977-88. PubMed ID: 23318953
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the Misfolding Mechanism of Transthyretin Monomer: Insights from Hybrid-Resolution Simulations and Markov State Model Analysis.
Zhou S; Cheng J; Yang T; Ma M; Zhang W; Yuan S; Lo GV; Dou Y
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31861226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
